Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 11 bp deletion in exon1.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-ESRP2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
ESRP2 also known as Epithelial Splicing Regulatory Protein 2 plays a role in how RNA undergoes alternative splicing. This protein is part of the larger family of RNA-binding proteins that modulate the splicing of pre-mRNA in an epithelial cell context. ESRP2 has a molecular weight of approximately 76 kDa. It is expressed mainly in epithelial tissues including the lung kidney and intestine. Human ESRP2 encodes a protein that controls variations in mRNA which leads to different protein isoforms.
Biological function summary
ESRP2 regulates epithelial cell phenotypes by influencing the expression of genes specific to epithelial tissues. It forms a complex with ESRP1 another RNA-binding protein enhancing its ability to control RNA splicing events. The ESRP2 protein affects the alternative splicing of pre-mRNAs encoding proteins that contribute to cell adhesion motility and signaling pathways. This precise regulation of mRNA variants is critical for maintaining epithelial cellular identity and function.
Pathways
The involvement of ESRP2 in RNA splicing impacts the epithelial-mesenchymal transition (EMT) pathway. This is key in developmental processes and cancer metastasis where ESRP2 partners with ESRP1 to regulate the splice variants of genes important for EMT like FGFR2. ESRP2 affects the inclusion or exclusion of certain exons driving variation in receptor forms that have different biological outcomes influencing cell signaling and adhesion properties.
ESRP2 has significant associations with cancer progression particularly in epithelial tumors such as breast cancer and prostate cancer. Abnormal ESRP2 expression can lead to changes in EMT-related gene splicing fostering metastasis and advanced tumor states. In the context of prostate cancer ESRP2 interacts with FGFR2 and influences cancer cell invasiveness by altering specific splicing patterns highlighting its potential as a therapeutic target in cancer treatment.
